TABLE 1.
Virus | Name in this study | Subtype | Intravenous pathogenicity index | Patient symptomsa | MID50b | LD50b | % Maximum wt lossc | HA cleavage site sequencea |
---|---|---|---|---|---|---|---|---|
A/Netherlands/219/03 | NL/219 | H7N7 | HPAI | Fatal ARDS | 0.76 | 2.5 | 23.7 | PEIPKRRRR/G |
A/Netherlands/230/03 | NL/230 | H7N7 | HPAI | Conjunctivitis | 2.5 | >7 | 14.5 | PEIPKRRRR/G |
A/Ck/Netherlands/1/03 | Ck/NL/1 | H7N7 | HPAI | NA | 3.25 | >7 | 12.5 | PEIPKRRRR/G |
A/Canada/504/04 | Can/504 | H7N3 | HPAI | Conjunctivitis | 2.25 | >7 | 2.5 | PENPKQAYQKRMTR/G |
A/Canada/444/04 | Can/444 | H7N3 | LPAI | Conjunctivitis | 2.5 | >7 | 2.5 | PENPKQAYQKQMTR/G |
A/NY/107/03 | NY/107 | H7N2 | LPAI | Respiratory symptoms | 2.25 | >7 | 12.2 | PEKPKPR/G |
A/Tky/VA/4529/02 | Tky/VA | H7N2 | LPAI | NA | 1.76 | >7 | 3.5 | PEKPKPR/G |
A/Ck/CT/260413-2/03 | Ck/CT | H7N2 | LPAI | NA | 2.25 | >7 | 10.1 | PEKPKPR/G |
A/GH/Mass/148081-11/02 | GH/Mass | H7N2 | LPAI | NA | 1.5 | >7 | 16.1 | PEKPKKR/G |